{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:47:00Z","timestamp":1778320020414,"version":"3.51.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T00:00:00Z","timestamp":1523404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1093\/aje\/kwy076","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T15:10:01Z","timestamp":1523373001000},"page":"1856-1862","source":"Crossref","is-referenced-by-count":13,"title":["Real-World Evidence for Regulatory Decisions: Concomitant Administration of Zoster Vaccine Live and Pneumococcal Polysaccharide Vaccine"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8277-2431","authenticated-orcid":false,"given":"Katia","family":"Bruxvoort","sequence":"first","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2762-9266","authenticated-orcid":false,"given":"Lina S","family":"Sy","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung Fu","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,4,11]]},"reference":[{"key":"key\n\t\t\t\t20180831110421_kwy076C1","author":"US Food and Drug Administration","year":"2017"},{"issue":"23","key":"key\n\t\t\t\t20180831110421_kwy076C2","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180831110421_kwy076C3","author":"Berger","year":"2017"},{"issue":"8","key":"key\n\t\t\t\t20180831110421_kwy076C4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.2017.9991","article-title":"Multidimensional evidence generation and FDA regulatory decision making: defining and using \u201creal-world\u201d data","volume":"318","author":"Jarow","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"key\n\t\t\t\t20180831110421_kwy076C5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMra1614394","article-title":"Evidence for health decision making\u2014beyond randomized, controlled trials","volume":"377","author":"Frieden","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180831110421_kwy076C6","author":"US Food and Drug Administration","year":"2016"},{"key":"key\n\t\t\t\t20180831110421_kwy076C7"},{"issue":"24","key":"key\n\t\t\t\t20180831110421_kwy076C8","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMsb1610128","article-title":"Transforming evidence generation to support health and health care decisions","volume":"375","author":"Califf","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180831110421_kwy076C9","author":"Pneumovax","year":"2015"},{"key":"key\n\t\t\t\t20180831110421_kwy076C10","author":"Zostavax","year":"2017"},{"key":"key\n\t\t\t\t20180831110421_kwy076C11","author":"US Food and Drug Administration","year":"2016","journal-title":"Summary Basis for Regulatory Action [for Zostavax (zoster vaccine live)]"},{"key":"key\n\t\t\t\t20180831110421_kwy076C12","first-page":"894","article-title":"Concomitant administration of zoster and pneumococcal vaccines in adults \u226560 years old","author":"MacIntyre","year":"2010"},{"issue":"48","key":"key\n\t\t\t\t20180831110421_kwy076C13","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1016\/j.vaccine.2011.08.046","article-title":"Perspective of the US Food and Drug Administration on concomitant administration of Zostavax and Pneumovax","volume":"29","author":"Baylor","year":"2011","journal-title":"Vaccine"},{"issue":"20","key":"key\n\t\t\t\t20180831110421_kwy076C14","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1016\/j.vaccine.2011.04.019","article-title":"Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection","volume":"29","author":"Oxman","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"key\n\t\t\t\t20180831110421_kwy076C15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/653605","article-title":"Zoster vaccine: current status and future prospects","volume":"51","author":"Oxman","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"6","key":"key\n\t\t\t\t20180831110421_kwy076C16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"issue":"9","key":"key\n\t\t\t\t20180831110421_kwy076C17","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1086\/379048","article-title":"Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine","volume":"188","author":"Levin","year":"2003","journal-title":"J Infect Dis"},{"issue":"20","key":"key\n\t\t\t\t20180831110421_kwy076C18","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1016\/j.vaccine.2011.03.018","article-title":"Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine","volume":"29","author":"Tseng","year":"2011","journal-title":"Vaccine"},{"issue":"RR-5","key":"key\n\t\t\t\t20180831110421_kwy076C19","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"key\n\t\t\t\t20180831110421_kwy076C20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7812\/TPP\/12-031","article-title":"Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data","volume":"16","author":"Koebnick","year":"2012","journal-title":"Perm J"},{"issue":"7","key":"key\n\t\t\t\t20180831110421_kwy076C21","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"issue":"7040","key":"key\n\t\t\t\t20180831110421_kwy076C22","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/bmj.312.7040.1215","article-title":"Why we need observational studies to evaluate the effectiveness of health care","volume":"312","author":"Black","year":"1996","journal-title":"BMJ"},{"issue":"2","key":"key\n\t\t\t\t20180831110421_kwy076C23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jama.2010.1983","article-title":"Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease","volume":"305","author":"Tseng","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"key\n\t\t\t\t20180831110421_kwy076C24","first-page":"1","article-title":"General recommendations on immunization\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"National Center for Immunization and Respiratory Diseases","year":"2011","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"key\n\t\t\t\t20180831110421_kwy076C25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.amepre.2016.08.031","article-title":"National and state-specific shingles vaccination among adults aged \u226560 years","volume":"52","author":"Lu","year":"2017","journal-title":"Am J Prev Med"},{"issue":"11","key":"key\n\t\t\t\t20180831110421_kwy076C26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6611a1","article-title":"Surveillance of vaccination coverage among adult populations\u2014United States, 2015","volume":"66","author":"Williams","year":"2017","journal-title":"MMWR Surveill Summ"},{"key":"key\n\t\t\t\t20180831110421_kwy076C27","author":"Shingrix","year":"2017"},{"issue":"3","key":"key\n\t\t\t\t20180831110421_kwy076C28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"key\n\t\t\t\t20180831110421_kwy076C29","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"key\n\t\t\t\t20180831110421_kwy076C30","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"key\n\t\t\t\t20180831110421_kwy076C31","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMp1705800","article-title":"The fate of FDA postapproval studies","volume":"377","author":"Woloshin","year":"2017","journal-title":"N Engl J Med"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/aje\/article-pdf\/187\/9\/1856\/25639562\/kwy076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T19:06:03Z","timestamp":1571079963000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/187\/9\/1856\/4967862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,11]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,4,11]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwy076","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9]]},"published":{"date-parts":[[2018,4,11]]}}}